GHK-Cu, prescribed — not just shipped.

GHK-Cu is a tripeptide — glycyl-L-histidyl-L-lysine — bound to a copper ion. It occurs naturally in human plasma and other body fluids, and measured levels decline with age. Research interest centers on how it transports copper into cells and on its signaling role in skin remodeling and collagen synthesis. Much of that work is laboratory and topical research rather than large human trials of an injectable form, so the mechanism is better described than the outcomes.

Yes. GHK-Cu is available through Promise only by prescription. You complete an intake questionnaire, a licensed provider reviews your health history, and they prescribe only when treatment is appropriate for you.

No. GHK-Cu is not FDA-approved. It is a compounded medication, and compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. It is prepared by a licensed U.S. compounding pharmacy against a prescription written for you specifically, after a licensed provider has reviewed your health history.

You start with the intake form for GHK-Cu, which is its own clinical questionnaire covering your health history, medications, and goals. A licensed provider reviews your answers and prescribes only if GHK-Cu is appropriate for you. If it is, your medication is compounded and dispensed by a licensed U.S. pharmacy and shipped in temperature-safe packaging, with follow-up check-ins from your care team.

GHK-Cu on its own is a single peptide, dosed and adjusted on its own terms. KLOW is a blend, and GHK-Cu is one of the peptides in it, combined with others in a single compounded formulation. Which of the two makes sense depends on what you and your provider are trying to address and on what else you are taking; a single compound is easier to evaluate in isolation, while a blend covers more ground at once. That is a clinical decision.